HealthLynked Corp.
1.6300+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · HLYK · USD
Key Stats
Market Cap
4.64MP/E (TTM)
-Basic EPS (TTM)
-2.00Dividend Yield
0%Recent Filings
8-K
Reverse split boosts share price
HealthLynked Corp. executed a 1-for-100 reverse stock split effective September 4, 2025, slashing outstanding shares from 284,778,332 to 2,847,784 while keeping authorized shares at 500,000,000. This non-dilutive move boosts per-share price to attract institutional investors and enable uplisting. It strengthens capital structure amid AI platform scaling and insurance talks. Forward-looking plans hinge on execution risks.
10-Q
Q2 FY2025 results
HealthLynked's Q2 FY2025 revenue fell 25% y/y to $592K, driven by a 25% drop in patient services to $573K after discontinuing its OB/GYN practice, while subscriptions dipped 13% to $7K and products halved to $12K; yet operating costs plunged 45%, yielding a narrower $435K operating loss versus $1.1M last year. For the half-year, revenue slid 24% y/y to $1.4M with a $1.1M operating loss, improved from $2.3M prior, as practice expenses fell 37% on staffing cuts. Cash dwindled to $20K amid $850K operating burn, offset by $794K in related-party notes; total debt hit $5.3M, mostly short-term convertible to CEO. Free cash flow not disclosed in the 10-Q. Competition from larger health platforms shadows growth.
10-Q
Q1 FY2025 results
HealthLynked's Q1 revenue fell 23% y/y to $774K, driven by a 22% drop in patient services to $752K after discontinuing its OB/GYN practice, while subscriptions rose 26% to $9.6K and products slid 62% to $12.6K; operating loss narrowed 48% to $617K as practice costs plunged 33% and SG&A cut 37%. Net loss improved 24% to $1.1M, though amortization of debt discounts jumped 274% to $405K from heavier borrowing. Cash dwindled to $22K amid $433K operating burn, offset by $379K in financing inflows, leaving total debt at $4.6M and a $4M working capital deficit. Contingent $1.5M from a prior sale hangs in the balance. Regulatory scrutiny on Medicare and Medicaid reimbursements poses ongoing risks.
10-K
FY2024 results
HealthLynked Corp. posted FY2024 revenue of $3.0M, down 47% y/y, as patient services fell 48% to $2.9M amid physician departures at NCFM and NWC, while subscriptions and product sales dropped 45% and 42%, respectively; Q4 saw sequential revenue stabilization but persistent losses, with operating expenses trimmed 22% y/y through cost cuts, yet impairment charges on NCFM assets hit $716K. Q4 momentum faltered with NCFM revenue down 65% y/y and 35% q/q, dragging margins amid staffing reductions, while Digital Healthcare subscriptions decelerated and Medical Distribution sales softened on muted demand. Liquidity tightened to $76K cash against $3.0M working capital deficit, funded by $3.3M in related-party notes and $0.4M equity raises, with no dividends or buybacks. No annual guidance disclosed; going concern doubt persists without fresh capital.
8-K
Debt extension and new note issued
HealthLynked issued a $420,000 convertible promissory note to a trust controlled by CEO Dr. Michael Dent on March 20, 2025, formalizing undocumented advances from 2024, with 12% interest rising to 18% on default and maturity on September 20, 2025; conversion is possible at $0.0375 per share. The company also extended twelve existing notes totaling $1,216,500 to the same date, hiking interest to 15% and issuing a ten-year warrant for 1,353,356 shares at $0.0375. Funds support working capital. Related-party ties heighten oversight needs.
IPO
Website
Employees
Sector
Industry
CAH
Cardinal Health, Inc.
164.47+1.68
DH
Definitive Healthcare Corp.
2.77-0.17
HCA
HCA Healthcare, Inc.
468.40+1.94
HWAIF
HealWELL AI Inc.
1.04-0.02
HYDTF
Hydreight Technologies Inc
3.28-0.09
MCK
McKesson Corporation
807.63+3.04
NHC
National HealthCare Corporation
120.85-1.15
SNYR
Synergy CHC Corp.
2.26-0.14
SYRA
Syra Health Corp.
0.07+0.00
WHTCF
Well Health Technologies Corp.
3.60-0.14